


 Cite this: *RSC Adv.*, 2022, **12**, 28553

Functionalisation of vitamin B₁₂ derivatives with a cobalt β -phenyl ligand boosters antimetabolite activity in bacteria†

 Christopher Brenig, Paula Daniela Mestizo and Felix Zelder *

This study describes the syntheses of four singly- and two doubly-modified vitamin B₁₂ derivatives for generating antimetabolites of *Lactobacillus delbrueckii* (*L. delbrueckii*). The two most potent antagonists, a Co β -phenyl-cobalamin-*c*,8-lactam and a 10-bromo-Co β -phenylcobalamin combine a *c*-lactam or 10-bromo modification at the "eastern" site of the corrin ring with an artificial organometallic phenyl group instead of a cyano ligand at the β -site of the cobalt center. These two doubly-modified B₁₂ antagonists (10 nM) inhibit fully B₁₂-dependent (0.1 nM) growth of *L. delbrueckii*. In contrast to potent 10-bromo-Co β -phenylcobalamin, single modified 10-bromo-Co β -cyanocobalamin lacking the artificial organometallic phenyl ligand does not show any inhibitory effect. These results suggest, that the organometallic β -phenyl ligand at the Co center ultimately steers the metabolic effect of the 10-bromo-analogue.

Received 12th September 2022

Accepted 27th September 2022

DOI: 10.1039/d2ra05748d

rsc.li/rsc-advances

1. Introduction

Non-functional analogues of vitamins and vitamin building blocks represent an important class of drugs and drug candidates for treating different classes of diseases ranging from bacterial and fungal infections to human cancer.^{1–3} In the first half of the 20th century, prontosil was introduced as the first commercially available antimicrobial agent and saved millions of lives.⁴ The sulfonamide-based drug targets effectively bacterial, but not human biosynthesis of vitamin B₉ (folic acid) explaining its selective therapeutic effect. Modified folic acid derivatives such as methotrexate, trimetrexate or pemetrexed represent other examples of important antibacterial and anti-cancer agents by inhibiting folic acid-dependent enzymatic transformations.^{1,5,6} In contrast to these folate-based drugs, modified cobalamin (vitamin B₁₂) derivatives have not been developed so far to approved antibacterial or anticancer drugs.⁷ Nevertheless, some singly-modified vitamin B₁₂ derivatives showed promising inhibitory effects on B₁₂-dependent pathways.⁸ For example, B-ring-modified hydroxycobalamin-*c*,8-lactam (Fig. 1B left) and β -ligand-modified 4-ethylphenylcobalamin (Fig. 1B right) decreased significantly the activities of liver L-methylmalonyl coenzyme A mutase and methionine synthase as indicated by elevated plasma methylmalonic acid concentration and total homocysteine

concentration in rodents.^{9,10} In contrast to these important results, bi-functionalised B₁₂ derivatives combining two instead of a single modification were not explored so far in a systematic fashion.

Herein we report on the antibacterial activity of doubly-modified B₁₂ derivatives. It is demonstrated in a proof-of-concept study with *L. delbrueckii*, that a specific second




Fig. 1 (A) General structural formula of cobalamins (Cbls; L = CN, R = H, x = 2 for vitamin B₁₂, 1; the natural f-side chain of Cbls is depicted in blue). The upper (β -) axial ligand (turquoise), B-ring subunit (green) and the C10 position (violet) are highlighted as target sites for chemical modification. (B) Schematic depictions of B₁₂ antimetabolites with a single modification at either the B-ring (left) or upper-ligand (right) modification. The effect on the increase of important biomarkers MMA (methylmalonic acid) and Hcy (homocysteine) of B₁₂-dependent metabolism in mammals is indicated.^{9,10} (C) Schematic depiction of the most potent B₁₂ antimetabolite of *L. delbrueckii* combining two chemical modifications at the upper ligand and the C10 position developed in this work.

Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH 8057 Zurich, Switzerland. E-mail: felix.zelder@chem.uzh.ch; Web: <http://www.felix-zelder.net>; Fax: +41 44 635 6803

† Electronic supplementary information (ESI) available. See <https://doi.org/10.1039/d2ra05748d>



structural modification (*i.e.* with an artificial organometallic phenyl instead of a cyano ligand at the β -side of the Co^{III} centre) steers the metabolic effect toward the desired activity as an antimetabolite.


2. Results and discussion

2.1 Syntheses and characterisation of modified vitamin B_{12} derivatives

Starting from vitamin B_{12} (1; Fig. 1A) we prepared two novel bi-functionalized Cbls (4 and 7; Scheme 1) using established synthetic protocols.¹¹ In particular, we combined in the analogues either a *c*,₈-lactam¹¹ (Scheme 1 left) or C10-Br¹² (Scheme 1 right) modification at the corrin ring with a β -phenyl ligand at the Co-center (Scheme 1, bottom line). These combinations were purposefully chosen because the selected transformations (i) induced biological effects in previous studies when incorporated into the Cbl scaffold (Fig. 1B) and (ii) provide analogs in high purity under mild conditions.^{9,10}

Syntheses, isolation, and characterization of the two novel doubly-modified derivatives 4 and 7 and four singly-modified Cbls (2, 3, 5 and 6) are described in more detail below and in the Experimental section. In this section, we outline only the preparation and characterization of unprecedented compounds $\text{Co}_{\beta}\text{-phenyl-Cbl-}\text{c},\text{8-lactam}$ (4; Scheme 2 top) and 10-bromo- $\text{Co}_{\beta}\text{-phenylcobalamin}$ (7; Scheme 2 bottom).

Vitamin B_{12} analogue 4 was synthesized in two steps starting from commercially available B_{12} in a total isolated yield of 27%. First, *c*,₈-lactam 2 was prepared under basic conditions at 100 °C following a procedure of Todd *et al.*¹¹ After reduction of its Co^{III} center with NaBH_4 (10 equiv.) and subsequent treatment with diphenyl iodonium chloride (2 equiv.) in H_2O ,¹³ the



Scheme 2 Top: synthesis of $\text{Co}_{\beta}\text{-phenyl-Cbl-}\text{c},\text{8-lactam}$ (4) from vitamin B_{12} (1) in a two-step procedure via $\text{Co}_{\beta}\text{-cyano-Cbl-}\text{c},\text{8-lactam}$ (2) applying selective and high-yielding chemical transformations in aqueous media. Bottom: synthesis of 10-bromo- $\text{Co}_{\beta}\text{-phenylcobalamin}$ (7) starting from $\text{Co}_{\beta}\text{-phenylcobalamin}$ (8).¹³


organometallic target 4 was obtained. The occurrence of a pseudo molecular ion at $m/z = 1404.56$ ($[\text{M} + \text{H}]^+$, $m/z_{\text{calc.}}: 1404.60$ for $\text{C}_{68}\text{H}_{92}\text{CoN}_{13}\text{O}_{14}\text{P}^+$) in the ESI-MS spectrum of 4 indicated successful arylation at the Co center of 2, supported by the observation of a hypsochromically shifted γ -band ($\Delta\lambda = 18$ nm) with diminished intensity ($\Delta\log \epsilon = 0.22$) in the UV-vis spectrum. This spectral behavior is typical for organometallic Cbls featuring a $\text{Co}^{\text{III}}\text{-C}$ bond (Fig. S13†).¹³ For the synthesis of 10-bromo- $\text{Co}_{\beta}\text{-phenylcobalamin}$ (7; Scheme 2 bottom), we considered that Cbls bearing good leaving groups are prone towards reducing agents. Therefore, 10-bromo- $\text{Co}_{\beta}\text{-cyanocobalamin}$ (5) is not compatible with arylation conditions using NaBH_4 .¹⁴ Having this in mind, we brominated the previously described $\text{Co}_{\beta}\text{-phenylcobalamin}$ (8)¹³ with *N*-bromosuccinimide (NBS) at its C10 position according to a method of Wagner.¹⁴ ESI-MS analysis confirmed successful formation of 7 by the presence of its adduct ion peak at $m/z = 1485.53$ ($[\text{M} + \text{H}]^+$) and the characteristic bromine isotopic pattern. Bromination at position C10 of 7 was further proven by the absence of the signal of the proton at C10 in the ¹H-NMR spectrum and the absorption spectrum of 7 exhibited a characteristic redshift of the $\alpha\beta$ -band to 537 nm.¹²

2.2 Bacterial growth assays

The inhibitory potential of the small library of four singly-, and two doubly modified B_{12} derivatives (2–7) was assessed with bacterial growth assays using *L. delbrueckii*.

These Gram-positive bacteria are ideal for such proof-of-concept studies since they possess ribonucleotide reductase (RNR) as the only Cbl-dependent enzyme (see Fig. 2 for details).^{15–17} Small concentrations of B_{12} (0.1 nM) in the medium are sufficient to support growth of *L. delbrueckii* (positive control; Fig. 3).

Notably, when exogenous B_{12} was absent in the assay medium (negative control), substantial residual growth (r.g.; 80 ± 1%) was still observed suggesting contamination of the B_{12} -free medium with little amounts of Cbl.^{17–19} In competition



Scheme 1 Cascade of multiple chemical modifications of Cbls and their physiologic effect (promotion of growth or activity as antimetabolite; r.g. = residual bacterial growth compared to a B_{12} -only control group) on a *L. delbrueckii* bacterial culture (the strength of the effect is indicated with colors; green: growth promoting; orange: medium inhibition of growth; red: strong inhibition of growth). The scheme does not indicate the course of chemical reactions. Charges omitted for clarity.






Fig. 2 Schematic representation of the conversion of ribonucleotides to deoxyribonucleotides catalyzed by 5'-adenosylcobalamin-dependent ribonucleotide reductase in the metabolism of *L. delbrueckii*.¹⁵




Fig. 3 Left: growth of a suspension culture of *L. delbrueckii* in presence of derivatives 2 (brown rhombs), 3 (blue triangles) and 4 (orange hollow hexagons) ($c = 10$ nM) and B_{12} (1, $c = 0.1$ nM) vs. two control groups (positive control: red dots; containing only 1 (0.1 nM), negative control: black squares; containing only medium) at 37°C ($n = 3$). Right: growth of a suspension culture of *L. delbrueckii* in presence of derivatives 5 (turquoise marked squares), 6 (inverse blue triangles) and 7 (violet hexagons) ($c = 10$ nM) and B_{12} (1, $c = 0.1$ nM) vs. two control groups (positive control: red dots; containing only 1 (0.1 nM), negative control: black squares; containing only medium) at 37°C ($n = 3$).

assays with a 100-fold excess of analogs 2–7 (10 nM) over B_{12} , $c,8$ -lactam modified CNCbl 2 showed 22% inhibition (r.g. = $78 \pm 1\%$; Fig. 3 left) of B_{12} -triggered growth. Bi-functionalization of analog 2 with an additional organometallic β -phenyl ligand (*i.e.*, analog 4) strengthened further the antimicrobial activity (r.g. = $66 \pm 4\%$; Fig. 3 left). Inhibition in this competition assay was stronger than residual growth in the absence of exogenous B_{12} (*i.e.*, negative control) suggesting that total B_{12} in the medium was effectively outcompeted by the presence of analogue 4 (Fig. 3 left). In contrast to single modified $c,8$ -lactam 2, single-modified 10-BrCNCbl (5) had no evident effects on B_{12} -dependent growth (r.g. = $100 \pm 1\%$; Fig. 3 right). This biological lethargy changed drastically upon further modification with a β -phenyl group at the Co^{III} center. Bi-functionalized 7 with a 10-Br modification was a comparably strong inhibitor (r.g. = $62 \pm 3\%$) as bi-functionalized 4 with a $c,8$ -lactam group (Fig. 3). The importance of the β -phenyl functionality at the Co^{III} center of inhibitors 4 and 7 for triggering the antimetabolic effect was further supported by studying the corresponding Co_β -aqua derivatives 3 and 6. These analogues lacking the organometallic phenyl ligand had either negligible (r.g. (3) = $96 \pm 3\%$, Fig. 3 left) or even growth-promoting effects (r.g. (6) = $129 \pm 1\%$, Fig. 3 right).

The latter result suggests, that aqua derivative 7 is still recognized, internalized, and metabolized by the microorganism to a growth promoting, enzymatically active organometallic AdoCbl cofactor (Fig. 3). In contrast, this reductive biological transformation is apparently not possible for 2, 4 and 7 containing σ -donating cyano or phenyl ligands in addition to a structurally altered Cbl scaffold.²⁰ Although we propose herein inhibition of RNR with inhibitors 2, 4 and 7 (Fig. 3), the actual biological target(s) and modes of action of these B_{12} analogues have still to be unraveled in future biological studies. So far, our proof-of-concept studies clearly demonstrate that the second, ligand-centered modification of the analogues with a β -phenyl ligand significantly steers antimetabolic activity. Replacement of this ligand with a weakly coordinating aqua ligand effected complete reversal of the antimetabolic activity of both bi-functionalized derivatives.

3. Conclusions

We have synthesized and tested antibacterial activity of four single- and two novel bi-functionalised B_{12} analogues. B_{12} -dependent growth studies with *L. delbrueckii* showed strikingly that doubly modified Co_β -phenyl-cobalamin- $c,8$ -lactam and 10-bromo- Co_β -phenylcobalamin were the most potent antagonists. Of note, inhibition was even stronger than residual growth in the absence of exogenous B_{12} . Moreover, these studies demonstrated strikingly, that the second, β -axial modification significantly steers the metabolic effect. In particular, the incorporation of an organometallic β -phenyl ligand at the cobalt center either empowered the inhibitory potential of CNCbl- $c,8$ -lactam or more interestingly, induced antimetabolic activity in an erstwhile innocent 10-brominated Cbl analogue.

4. Experimental section

4.1 General

Chemicals were of reagent grade quality or better and obtained from Sigma-Aldrich, ACROS Organics, Merck or Fluka and used without further purification unless otherwise indicated. Vitamin B_{12} was obtained from Sigma-Aldrich or received as a generous gift from DSM Nutritional Products AG (Basel/Switzerland) and Prof. Em. Bernhard Jaun (ETH Zurich, Switzerland). All solvents were of reagent, analytical, HPLC or LC-MS grade, respectively, and obtained from commercial suppliers. Bi-distilled H_2O was used in all reactions. H_2O from a Milli-Q (Merck-Millipore) water purification system was used for UV/vis spectroscopy, mass spectrometry and when indicated. Reactions were carried out under N_2 (g) or Ar (g) in oven-dried (100°C) glass equipment and monitored for completion by analysing a small sample (after suitable workup) by LC-MS. Evaporation of the solvents *in vacuo* was done with the rotary evaporator (Büchi) at the given bath temperature and pressure. SepPak® RP-18 cartridges (Waters) were applied for solid phase extraction. The compounds were dissolved in H_2O , transferred to the adsorbent, washed with H_2O or the indicated aq. soln, followed by H_2O , and eluted with CH_3OH .



4.2 Chromatography

Preparative HPLC. Separations were conducted on a LaPrep Sigma HPLC system (Knauer/VWR) equipped with a UV detector, a sample collector and a Nucleosil 100-7 C18 250/40 column (Macherey-Nagel). Method A: a gradient (0 min 5.0% A, 0–30 min 80% A, 30.1–40 min 95% A, 40.1–50 min 95% A) of CH₃CN (solvent A) *vs.* an aq. soln of 0.1% CF₃COOH (solvent B) was applied using a flow rate of 30 mL min⁻¹. Method B: a gradient (0 min 15% A, 0–30 min 80% A, 30.1–40 min 95% A, 40.1–50 min 95% A) of CH₃OH (solvent A) *vs.* an aq. soln of K₂HPO₄/KH₂PO₄ (10 mM, pH 7.0; solvent B) was applied using a flow rate of 30 mL min⁻¹. Method C: a gradient (0 min 5.0% A, 0–30 min 65% A, 30.1–40 min 95% A, 40.1–50 min 95% A) of CH₃OH (solvent A) *vs.* an aq. soln of K₂HPO₄/KH₂PO₄ (10 mM, pH 7.0; solvent B) was applied using a flow rate of 30 mL min⁻¹. LC-MS was performed on an ACQUITY UPLC system (Waters) equipped with a PDA detector and an autosampler using an ACQUITY UPLC BEH C18 Gravity 1.7 μ m (2.1 mm \times 50 mm) reversed phase column (Waters). The UPLC system was connected to a HCT ESI-MS spectrometer (Bruker Daltonics), operated in positive or negative mode; nebulizer pressure 60 psi, dry gas flow rate 10 L min⁻¹, dry gas temperature 365 °C, scan range *m/z* 200–2000. Samples were dissolved in H₂O, CH₃OH or CH₃CN and a total volume of 2.0 μ L of the sample was analyzed; Method 1: a gradient (0 min 5.0% A, 0.5–2.0 min 5–30% A, 2.01–4.0 min 30–100% A, 4.01–5.0 min 100% A) of CH₃CN (solvent A) *vs.* an aq. soln of 0.1% HCOOH (solvent B) was applied using a flow rate of 0.3 mL min⁻¹. Method 2: a gradient (0 min 5.0% A, 0.5–2.0 min 5–30% A, 2.01–4.01 min 30–100% A, 4.01–5.0 min 100% A) of CH₃CN (solvent A) *vs.* an aq. soln of 0.1% HCOOH (solvent B) was applied using a flow rate of 0.5 mL min⁻¹. High resolution electrospray ionization mass spectrometry (HR-ESI-MS) was performed on a Dionex Ultimate 3000 UHPLC system (Thermo Fischer Scientifics, Germering, Germany) connected to a QExactive MS with a heated ESI source (Thermo Fisher Scientific, Bremen, Germany); onflow injection of 1 μ L sample (*c* = approx. 50 μ g mL⁻¹ in the indicated solvent) with an XRS auto-sampler (CTC, Zwingen, Switzerland); flow rate 120 μ L min⁻¹; ESI: spray voltage 3.0 kV, capillary temperature 280 °C, sheath gas 30 L min⁻¹, aux gas 8 L min⁻¹, s-lens RF level 55.0, aux gas temperature 250 °C (N₂); full scan MS in the alternating (+)/(-)-ESI mode; mass ranges 80–1200 *m/z*, 133–2000 *m/z*, or 200–3000 *m/z* at 70 000 resolution (full width half-maximum); automatic gain control (AGC) target of 3.00 \times 10⁶; maximum allowed ion transfer time (IT) 30 ms; mass calibration to <2 ppm accuracy with Pierce® ESI calibration solns (Thermo Fisher Scientific, Rockford, USA); lock masses: ubiquitous erucamide (*m/z* 338.34174, (+)-ESI) and palmitic acid (*m/z* 255.23295, (-)-ESI).

4.3 Spectroscopy

UV/vis spectra. Cary 50 Scan spectrophotometer (Varian) or Specord 250 Plus (Analytik Jena) using 1 cm quartz cuvettes (Hellma Analytics); λ_{max} ($\log \epsilon$) in nm. Both ¹H- and ¹³C-NMR spectra were carried out at 298 K in D₂O or CD₃OD and at 500

MHz or 126 MHz, respectively. The ¹H-NMR spectra were performed in an AVANCE NEO 500 MHz spectrometer (Bruker) using a 5 mm-z-gradient RT-BBI probehead; δ in ppm relative to HDO (δ 4.79; corresponds to TMS (δ 0.00)) or CHD₂OD (δ 3.31; corresponds to TMS (δ 0.00)), *J* in Hz. Spectra in D₂O were presaturated. The ¹³C-NMR spectra were performed in an AVANCE NEO 500 MHz spectrometer (Bruker) using a 5 mm z-gradient CP-BBO probehead; δ in ppm relative to CD₃OD (δ 49.0; corresponds to TMS (δ 0.0)), *J* in Hz.

4.4 Bacterial growth assays

Culture medium was prepared by dissolving MRS broth (Difco) for *Lactobacilli* (5.5 g) in Milli-Q H₂O (100 mL) and subsequently filtered through a sterile 2.0 μ m filter. The culture medium (14 mL) was inoculated with *Lactobacillus delbrueckii* subsp. *Lactis*, DSM 20355 from a micro-ring culture (previously stored at -70 °C). The closed tubes were incubated at 30 °C for 24 h. Afterwards a small sample (0.5 mL) was taken out and OD_{680 nm} was determined and typically yielded values around 1.0 after 24 h. A second culture was inoculated by addition of the inoculate (200 μ L) to fresh MRS broth (14 mL), followed by incubation at 30 °C for 24 h, resulting in OD_{680 nm} = 1.5 prior to the conduction of the assay. The bacterial culture was centrifuged (5000 rpm/5 min), and the remaining pellet was suspended in H₂O ([NaCl] = 0.9%, 14.0 mL) and incubated at 37 °C for 30 min. The resulting suspension was centrifuged again (5000 rpm/5 min), followed by two washing steps in H₂O ([NaCl] = 0.9%, 14.0 mL) to remove remaining traces of the growth medium. Afterwards, H₂O ([NaCl] = 0.9%, 5.0 mL) was added to the pellet and the bacterial suspension was stored at 37 °C. Vitamin B₁₂ assay medium (Sigma-Aldrich, 41.5 g) was dissolved in Milli-Q H₂O (500 mL) and the mixt. was heated to 40 °C under stirring until everything was dissolved, before Tween® 80 (1.0 mL) was added and everything was thoroughly homogenized. The pH was adjusted to 6.0 by addition of H₂O ([NaOH] = 0.5 M) and the medium was filtered through a sterile 2.0 μ m filter. Subsequently, sterilized bacterial assay glass tubes (Fisher Scientific, total volume: 7.0 mL) were filled with of B₁₂ assay medium (6.5 mL), a sterile stock solution of vitamin B₁₂ in Milli-Q H₂O (6.5 μ L, 1.0 nM), except for the negative control, and a sterile soln of the respective test compound in H₂O (6.5 μ L, 100 nM to 0.1 μ M), except for the positive control. All tubes were finally inoculated with 40 μ L of the bacterial suspension, tightly closed, and incubated at 37 °C for 28–60 h. OD_{680 nm} was monitored photometrically every 2–8 h (after through mixing of the tubes), until saturation of growth was detected. All assays were performed in triplicates and average values of OD_{680 nm} ($\pm 2\sigma$) were obtained and plotted *vs.* time (*t*) in h (hours) to obtain growth curves. Residual growth values (r.g.) were estimated after 26 h and are given in% relative to the growth of the positive control group.

4.5 Experimental procedures

Co_β-cyanocobalamin-*c,8*-lactam (2). B-Ring lactam formation in Co_β-cyanocobalamin (**1**) was performed according to lit.¹¹ Briefly, **1** (100 mg, 73.8 μ mol, 1.0 equiv.) was added to



a soln of NaOH (1.0 M in H₂O, 20 mL) and the soln was heated to 100 °C for 10 min. The reaction mixture was adjusted to pH 8.0 by addition of NaHCO₃ and the crude product was extracted using SPE. Purification *via* preparative HPLC (method B) and subsequent lyophilization afforded 2 (46.6 mg, 34.4 μmol, 47%) as a red powdery solid.

UV-vis (H₂O, $c = 4.1 \times 10^{-5}$ M): 279 (3.92), 308 (3.69), 321 (3.63), 360 (4.20), 518 (3.64), 549 (3.66). UPLC: $t_{\text{ret}} = 1.70$ min (method 2). ESI-MS (H₂O/MeCN): $m/z = 677.58$ (100, [M + 2H]²⁺), 1353.55 (10, [M + H]⁺, $m/z_{\text{calc}}: 1353.56$ for C₆₃H₈₇CoN₁₄O₁₄P⁺). ¹H-NMR (D₂O, $c = 4.1 \times 10^{-5}$ M): 7.27 (s, HC7N), 7.09 (s, HC2N), 6.45 (s, HC4N), 6.31 (d, $J = 3.0$, HC1R), 5.93 (s, HC10), 4.67 (d, $J = 3.8$, ribose-CHOH), 4.30–4.20 (m, 2 corrin-CH), 4.11 (d, $J = 8.3$, corrin-CH), 4.07–3.99 (m, 2 corrin-CH), 3.91–3.85 (d-like m, H_a of H₂C5R), 3.70 (dd, $J = 12.8$, 3.8, H_b of H₂C5R), 3.55 (d, $J = 14.3$, H_a of H₂C175), 3.36–3.27 (m, HC13), 2.95–2.85 (m, H_b of H₂C175, corrin-CH), 2.79–2.41 (m, 5 corrin-CH₂) superimposed by 2.54 (s, H₃C151) and 2.52 (s, H₃C51), 3.40–2.31 (m, 5 corrin-CH₂), 2.10–1.73 (m, 4 corrin-CH₂) superimposed by 2.24 (s, dmbi-CH₃), 2.22 (s, dmbi-CH₃) and 1.84 (s, H₃C7A), 1.42 (s, H₃C12A), 1.37 (s, H₃C2A), 1.34–1.23 (m, corrin-CH₂) superimposed by 1.32 (s, H₃C17B), 1.21 (d, $J = 6.0$, H₃C177), 1.12 (s, H₃C12B), 0.45 (s, H₃C1A). Assignments were made in comparison with data from lit.^{21,22}

Co_β-aquacobalamin-*c,8*-lactam acetate (3). A soln of 2 (5.0 mg, 3.7 μmol) in H₂O (1.0 mL) was degassed by purging with N₂ (g) for 15 min, before a soln of NaBH₄ (1.5 mg, 40 μmol, 11 equiv.) in H₂O (0.1 mL) was added. The resulting mixt. was stirred at 23 °C for 10 min, until a color change to dark violet occurred. Subsequently, AgOAc (1.2 mg, 7.2 μmol, 1.9 equiv.) was added, resulting in formation of a white precipitate. The precipitate was filtered off and a gentle stream of air was passed through the remaining soln, upon which it turned red. LC-MS analysis (method 2) revealed formation of the aquo complex 3 as the sole product. The product was extracted using SPE, washed with an aq. soln of NH₄OAc (0.1 M, 10 mL) and eluted with CH₃OH. The solvent was evaporated *in vacuo* (200 mbar, 40 °C) and the residue was re-dissolved in H₂O (1.5 mL) and lyophilized overnight to afford 3 (5.1 mg, 3.7 μmol, quant.).

UV-vis (H₂O, $c = 2.2 \times 10^{-5}$ M): 276 (sh., 4.38), 290 (sh., 4.29), 349 (4.39), 404 (sh., 3.76), 495 (3.96), 523 (3.94). UPLC: $t_{\text{ret}} = 1.30$ –1.60 min (method 2). ESI-MS (H₂O/MeCN): $m/z = 664.02$ (100, [M–H₂O + H]²⁺, $m/z_{\text{calc}}: 663.78$ for C₆₂H₈₇CoN₁₃O₁₄P²⁺). ¹H-NMR (CD₃OD, $c = 7.3 \times 10^{-3}$ M): 7.87 (d, $J = 3.7$, OH), 7.22 (s, CH7N), 6.96 (s, HC2N), 6.59 (s, HC4N), 6.21 (d, $J = 3.1$, HC1R), 6.19 (s, HC10), 4.71–4.63 (m, ribose-CHOH), 4.36 (d, $J = 8.2$ Hz, corrin-CH), 4.19–4.15 (m, corrin-CH, ribose-CH), 4.13–4.09 (m, corrin-CH), 3.95 (dd, $J = 12.7$, 2.9, H_a of H₂C5R), 3.85 (d, $J = 9.5$, H_a of corrin-CH₂), 3.78 (dd, $J = 12.7$, 4.1, H_b of H₂C5R), 3.75–3.69 (m, corrin-CH), 3.51 (d, $J = 10.7$, H_b of corrin-CH₂), 3.36 (s, superimposed by CHD₂OD signal), 3.11–3.07 (m, corrin-CH), 3.04 (d, $J = 17.7$, corrin-CH), 2.88 (d, $J = 17.7$, corrin-CH), 2.85–2.73 (m, corrin-CH₂), 2.72 (s, corrin-CH₃), 2.69–2.48 (m, 5 corrin-CH₂) superimposed by 2.63 (2s, corrin-CH₃, CH₃COO), 2.45–2.37 (m, H_{a/b} of corrin-CH₂), 2.33 (s, dmbi-CH₃), 2.29 (s, dmbi-CH₃), 2.23–2.10 (m, 3 corrin-CH₂), 1.97 (s, corrin-CH₃), 1.94–1.82 (m, corrin-CH₂, H_{a/b} of corrin-CH₂), 1.66 (d, $J = 7.6$, H_{a/b} of corrin-

CH₂), 1.58 (s, corrin-CH₃), 1.53 (s, corrin-CH₃), 1.51–1.41 (m, corrin-CH₂), 1.38 (s, corrin-CH₃), 1.34 (s, corrin-CH₃), 1.29 (d, $J = 6.4$, H₃C177), 0.53 (s, H₃C1A). Assignments were made in comparison with data from lit.²²

Co_β-phenylcobalamin-*c,8*-lactam (4). In a Schlenk tube, 2 (25.0 mg, 18.5 μmol) was dissolved in H₂O (2.0 mL) and the solution was degassed using pump–freeze–thaw cycling (three cycles). To the degassed solution, NaBH₄ (6.90 mg, 182 μmol, 9.8 equiv.) was added under N₂ counterflow. The mixture was stirred at 23 °C for 30 min, until the solution turned dark brown. Subsequently, diphenyliodonium chloride (11.4 mg, 36.0 μmol, 1.9 equiv.) were added and the mixture was stirred at 23 °C for further 60 min, until LC-MS analysis (method 1) showed full conversion of the starting material and formation of two products with $m/z = 1404.6$ in a *ca.* 3 : 1 ratio, corresponding to the isomeric forms of 4. The raw products were isolated using SPE. Subsequent purification *via* prep. HPLC (method A), followed by crystallization from aqueous acetone, delivered Co_β-phenylcobalamin-*c,8*-lactam (4, 14.5 mg, 10.3 μmol, 56%) as pale red crystals and, after precipitation from MeOH/ethyl acetate, its side product 4a (Scheme S3, ESI[†]) (1.85 mg, 1.30 μmol, 7%) as an orange powder. 4a (Scheme S3, ESI[†]) was tentatively assigned according to ref. 13 and not further characterized.

UV-vis (H₂O, $c = 3.9 \times 10^{-5}$ M): 283 (4.09), 342 (3.98), 370 (3.80), 470 (sh., 3.55), 517 (3.73). UPLC: $t_{\text{ret}} = 2.45$ min (method 1). HRMS (ESI[†]): $m/z = 702.79905$ (100, [C₆₈H₉₁O₁₄N₁₃CoP + 2H]²⁺, $m/z_{\text{calc}}: 702.80150$), $m/z = 1404.59518$ (50, [M + H]⁺, $m/z_{\text{calc}}: 1404.59564$). ¹H-NMR (D₂O, $c = 1.2 \times 10^{-2}$ M) δ 7.34 (s, HC2N), 7.26 (s, HC7N), 6.81 (d, $J = 5.7$ Hz, HC4L), 6.76 (t, $J = 6.9$ Hz, HC3L, HC5L), 6.66 (s, HC4N), 6.29 (d, $J = 3.1$ Hz, HCR1), 5.89 (s, HC10), 5.79 (d, $J = 7.8$ Hz, HC2L, HC6L), 4.70 (td, $J = 8.4$, 4.3 Hz, HC3R), 4.42–4.33 (m, HC176), 4.30 (t, $J = 3.7$ Hz, HC2R), 4.20 (d, $J = 8.4$ Hz, HC3), 4.18–4.13 (m, HC4R), 3.97 (dd, $J = 12.9$, 2.5 Hz, H_a of H₂C5R), 3.78 (dd, $J = 13.0$, 4.2 Hz, H_b of H₂C5R), 3.57 (dt, $J = 14.0$, 2.3 Hz, H_a of H₂C175), 3.43 (d, $J = 10.3$ Hz, HC13), 3.36 (d, 10.0 Hz, HC19), 3.05–2.90 (m, H_a and H_b of H₂C71, H_b of H₂C175), 2.79 (s, H₃C51), 2.76–2.74 (t-like, $J = 5.9$ Hz, HC18), 2.70 (s, H₃C151), 2.68–2.61 (m, H_a and H_b of H₂C132, H_a of H₂C171), 2.58–2.47 (m, H₂C32, H_a of H₂C172), 2.44 (d, $J = 5.9$ Hz, H₂C181), 2.34 (s, H₃C10N), 2.31–2.23 (t-like, H₃C11N, H_b of H₂C172), 2.19–1.99 (m, H₂C82, H_a of H₂C131, H₂C31), 1.97–1.73 (m, H_b of H₂C131, H₂C21, H_b of H₂C171) superimposed by 1.92 (s, H₃C7A), 1.60–1.46 (m, H_a of H₂C81), 1.42 (s, H₃C12A), 1.29 (s, H₃C2A), 1.24 (d, $J = 6.3$ Hz, H₃C177), 1.18 (s, H₃C17B), 1.16–1.09 (m, H_b of H₂C81), 0.93 (s, H₃C12B), 0.55 (s, H₃C1A). ¹³C-NMR (D₂O, $c = 1.2 \times 10^{-2}$ M) δ 178.2 (C133), 178.0 (C33), 177.6 (C11), 176.5 (C72), 176.3 (C16), 176.3 (C83), 176.1 (C22), 176.0 (C182), 175.7 (C4), 174.9 (C173), 168.1 (C9), 163.8 (C14), 162.3 (C6), 144.3 (C1L), 142.4 (C2N), 137.7 (C8N), 133.9 (C5N), 133.0 (C2L, C6L), 131.8 (C6N), 130.1 (C9N), 127.3 (C3L, C5L), 124.8 (C4L), 118.8 (C4N), 110.9 (C7N), 106.5 (C5), 105.9 (C15), 90.4 (C10), 86.8 (C1R), 85.6 (C1), 81.7 (C4R), 75.6 (C19), 74.8 (C8), 72.9 (C3R), 72.5 (C176), 68.7 (C2R), 60.3 (C5R), 59.0 (C17), 56.0 (C3), 53.2 (C13), 50.9 (C7), 47.6 (C12), 46.1 (C2), 45.2 (C175), 43.7 (C71), 41.5 (C21), 38.4 (C18), 35.2 (C32), 34.4 (C132), 32.8 (C171), 32.2 (C172), 31.7 (C181), 29.7



(C12B), 29.4 (C81), 29.0 (C82), 27.9 (C131), 25.2 (C31), 21.0 (C1A), 20.0 (C7A), 19.9 (C12A), 19.8 (C10N), 19.1 (C11N), 18.8 (C177), 17.1 (C17B), 16.8 (C51), 16.2 (C2A), 15.2 (C151). Assignments were made based on 2D NMR studies (DQF-COSY, HSQC, HMBC, NOESY) and comparison with data from lit.¹³

10-Bromo-Co_β-cyanocobalamin (5). C10-bromination of 1 was performed based on a procedure published earlier by our group.¹² Under vigorous stirring, 1 (100 mg, 74 µmol, 1.0 equiv.) was dissolved in glacial acetic acid (3.0 mL). After purging with nitrogen for 10 min, NBS (13.0 mg, 74 µmol, 1.0 equiv.) was added to the stirred soln in small portions over time (3 h) at 23 °C. The solution turned dark purple upon addition. After complete addition, LC-MS analysis (method 1) showed full conversion of the starting material. The reaction mixture was diluted with H₂O (25 mL) and corrinoid material was extracted with SPE. Solvent was subsequently removed under reduced pressure and the crude product was purified by preparative HPLC (method C) affording 5 (72.2 mg, 50 µmol, 68%) as a dark purple powder after lyophilization.

UV-vis (H₂O, $c = 4.9 \times 10^{-5}$ M): 283 (3.69), 290 (3.71), 367 (4.13), 416 (sh., 3.15), 553 (3.51), 577 (3.55). UPLC: $t_{\text{ret}} = 2.05$ min (method 1). ESI-MS (H₂O/MeOH): $m/z = 718.21$ (100, [M + 2H]²⁺), 1435.45 (11, [M + H]⁺, $m/z_{\text{calc}}: 1435.48$ for C₆₃H₈₈BrCoN₁₄O₁₄P⁺). ¹H-NMR (D₂O, $c = 4.2 \times 10^{-3}$ M): 7.27 (s, HC7N), 7.09 (s, HC2N), 6.48 (s, HC4N), 6.34 (d, $J = 3.0$, HC1R), 4.74–4.70 (m, ribose-CHOH), 3.37 (dd, $J = 8.3, 6.8$, ribose-CHOH), 4.31–4.24 (m, corrin CH, ribose-CHOH), 4.20 (d, $J = 9.0$, corrin-CH), 4.03 (t, $J = 9.0, 2H$), 3.93–3.87 (m, 1H), 3.73 (dd, $J = 14.2, 3.4$), 3.59 (d, $J = 14.3$ Hz, corrin-CH), 3.35 (d, $J = 9.0$, corrin-CH), 2.94 (dd, $J = 14.3, 9.8$, corrin-CH), 2.76–2.59 (m, 5 corrin-CH₂), 2.58–2.52 (m, 2 corrin-CH₂) superimposed by 2.57 (s, corrin-CH₃) and 2.54 (s, corrin-CH₃), 2.40–2.15 (m, 2 corrin-CH₂), superimposed by 2.25 (s, corrin-CH₃) and 2.23 (s, corrin-CH₃), 2.11–1.75 (m, 3 corrin-CH₂) superimposed by 1.89 (s, corrin-CH₃) and 1.79 (s, corrin-CH₃), 1.36 (s, corrin-CH₃), 1.35 (s, corrin-CH₃), 1.29 (s, corrin-CH₃), 1.23 (d, $J = 6.0$, H₃C177), 1.21–1.06 (m, corrin-CH₂), 0.35 (s, corrin-CH₃). Data is in agreement with lit.¹²

10-Bromo-Co_β-aquacobalamin tetrafluoroborate (6). was synthesized via intermediate 10-bromo-Co_β-phenylethynylcobalamin (10-BrPhEtyCbl), as reported earlier in detail by our group.²⁰ To a soln of 10-BrPhEtyCbl (10.8 mg, 7.16 µmol, 1.0 equiv.) in H₂O (2.0 mL), a soln of HBF₄ (48% in H₂O, 100 µL, 34.3 mg HBF₄, 390 µmol) was added and the resultant bright purple soln was stirred at 40 °C for 10 min. LC-MS analysis (method 1) of the reaction mixture revealed successful de-alkynylation of the starting material, yielding 6 as the sole product, which was subsequently isolated from the reaction mixture using SPE, eluted with CH₃OH and the solvent was removed *in vacuo* (200 mbar, 40 °C). The residue was re-dissolved in H₂O and lyophilized overnight to yield 6 (10.5 mg, 6.94 µmol, 97%).

UV-vis (H₂O, $c = 1.1 \times 10^{-5}$ M): 280 (4.2), 289 (4.2), 357 (4.4), 421 (3.6), 532 (3.9), 555 (3.9). UPLC: $t_{\text{ret}} = 1.75$ min (method 1). ESI-MS (H₂O/MeCN): $m/z = 704.81$ (100, [M–H₂O + 2H]²⁺, $m/z_{\text{calc}}: 704.74$ for C₆₂H₈₈BrCoN₁₃O₁₄P²⁺). ¹H-NMR (D₂O, $c = 1.1 \times 10^{-3}$ M): 7.08 (s, HC7N), 6.44 (s, HC2N), 6.35 (s, HC4N), 6.16–6.14 (d-like m, HC1R), 4.23–4.10 (m, HC19, HC176, HC2R, HC8),

3.91 (d, $J = 8.3$, HC4R), 3.79 (d, $J = 12.0$, H_a of H₂C5R), 3.62 (d, $J = 12.0$, H_b of H₂C5R), 3.56–3.46 (m, H_a of C175, HC13), 2.90–2.77 (m, H_b of H₂C175, HC18), 2.71–2.38 (m, H₂C181, H₂C132 H_a of H₂C171, H₂C172) superimposed by 2.60 (s, H₃C151) and 2.54 (s, H₃C51), 2.36–2.27 (m, H₂C32, H_a of H₂C71), 2.22–1.69 (m, H₂C21, H₂C31, H_a of H₂C81, H_b of H₂C171, H₂C172, H₂C71) superimposed by 2.17 (s, H₃C10N), 2.13 (s, H₃C11N), 1.87 (s, H₃C7A) and 1.75 (s, H₃C12A), 1.42–1.10 (m, H_b of H₂C81, H₂C82) superimposed by 1.38 (s, H₃C2A), 1.33 (s, H₃C17B), 1.29 (s, H₃C12B) and 1.15 (d, $J = 6.0$, H₃C177), 0.31 (s, H₃C1A). Chemical shifts were identical with those published earlier.²⁰

10-Bromo-Co_β-phenylcobalamin (7). To a soln of 8 (10 mg, 7.1 µmol, 1.0 equiv.) in conc. acetic acid (0.5 mL), NBS (1.3 mg, 7.1 µmol, 1.0 equiv.) was added in small portions over a time period of 90 min at 23 °C under protection from light. The soln turned purple and was diluted with 0.1 M Tris buffer (pH = 8.0, 10 mL) and the raw product (no formation of Co_{α/β}-diastereomers observed) was extracted using SPE. Purification *via* prep. HPLC (method B) and crystallization from H₂O/MeCN afforded 7 (5.4 mg, 3.6 µmol, 51%) as bright purple needles.

UV-vis (H₂O, $c = 3.5 \times 10^{-5}$ M): 284 (4.04), 348 (4.00), 380 (sh., 3.79), 471 (sh., 3.47), 537 (br., 3.67). UPLC: $t_{\text{ret}} = 2.65$ min (method 1). HRMS (ESI+): $m/z = 742.76424$ (100, [C₆₈H₉₂O₁₄N₁₃–BrCoP + 2H]²⁺, $m/z_{\text{calc}}: 742.76481$), $m/z = 1484.52168$ (30, [M + H]⁺, $m/z_{\text{calc}}: 1484.52125$). ¹H-NMR (CD₃OD, $c = 8.7 \times 10^{-3}$ M): δ 8.30 (bs, HC2N), 7.41 (s, HC7N), 7.17 (s, HC4N), 6.74 (t, $J = 7.0$ Hz, HC4L), 6.60 (t, $J = 7.6$ Hz, HC3L–HC5L), 6.34 (d, $J = 4.2$ Hz, HC1R), 5.32 (d, $J = 7.3$ Hz, HC2L–HC6L), 4.62 (dd, $J = 2.8, 7.5$ Hz, HC3R), 4.53 (t-like, HC2R), 4.45–4.38 (m, HC4R), 4.38–4.30 (m, HC176), 3.88 (dd, $J = 12.4, 3.1$ Hz, H_a of H₂C5R), 3.76 (dd, $J = 12.4, 4.1$ Hz, H_b of H₂C5R), 3.57–3.46 (m, H_a of H₂C175, HC13, HC19), 3.05 (dd, $J = 13.9, 7.5$ Hz, H_b of H₂C175), 3.02–2.96 (m, HC18), 2.74 (s, H₃C51), 2.70–2.66 (d, H_a of H₂C71) superimposed by 2.67 (s, H₃C151), 2.65–2.53 (m, H_a of H₂C171, H₂C132), 2.49–2.33 (m, H₂C32, corrin-CH₂, H_a of H₂C172) superimposed by 2.40 (s, H₃C10N) and 2.37 (s, H₃C11N), 2.28–2.14 (m, H_b of H₂C171, H_a of H₂C82, H_a of corrin-CH₂, H_b of H₂C172), 2.10–2.00 (m, H₂C31, H_b of H₂C82), 1.95 (d, H_a of H₂C21) superimposed by 1.96 (s, H₃C7A), 1.90–1.87 (d, H_b of H₂C21) superimposed by 1.87 (s, H₃C12A), 1.79–1.67 (m, H_b of corrin), 1.64 (d, $J = 14.1$ Hz, H_b of H₂C71), 1.35 (s, H₃C2A), 1.23 (d, $J = 6.2$ Hz, H₃C177), 1.18 (s, H₃C17B), 1.14 (s, H₃C12B), 0.90 (s, H₃C1A). ¹³C-NMR (CD₃OD, $c = 8.7 \times 10^{-3}$ M): δ 178.1, 177.9, 177.6, 177.5, 176.9, 175.9, 175.4, 174.9, 174.6, 173.0, 165.9, 164.0, 142.6 (C2N), 135.4, 134.1 (C2L, C6L), 131.8, 130.3, 128.2 (C3L, C5L), 126.3 (C4L), 118.0 (C4N), 112.9 (C7N), 111.2, 107.9, 94.2 (C10), 88.2, 87.6 (C1R), 85.7, 77.2 (C19), 75.8 (C3R), 74.5, 73.1, 72.3, 62.8, 60.9, 58.2, 57.8, 57.7, 57.5, 57.3, 57.1 (C3), 57.1 (C13), 52.2, 47.1, 46.5 (C175), 43.5 (C71), 42.4 (C21), 39.8 (C18), 36.4 (C32), 34.4, 34.3 (C132), 34.2 (C172), 33.4, 33.0 (C171), 28.9, 28.7 (C82), 27.8 (C12B), 26.9 (C31), 23.9 (C12A), 23.6 (C1A), 20.7 (C10N), 20.5 (C11N), 20.0 (C177), 19.8 (C7A), 19.1 (C17B), 17.3 (C51), 17.2 (C2A), 17.0 (C151). Assignments were made based on 2D NMR studies (HSQC and HMBC) and comparison with data of 4.

Co_β-phenylcobalamin (8; β-PhCbl). was synthesized using a modified literature procedure.¹³ In a Schlenk tube, Co_β-aquacobalamin chloride (25.0 mg, 18.1 µmol, 1 equiv.) was



dissolved in H_2O (2.0 mL). After degassing by pump-freeze-thaw cycling (three cycles), sodium borohydride (6.90 mg, 180 μmol , 10 equiv.) was added under N_2 counterflow. Upon addition, the solution turned dark brown, and the mixture was stirred at 23 °C for 30 min, before diphenyliodonium chloride (11.5 mg, 37.0 μmol , 2.0 equiv.) was added. The solution was protected from light and stirred at 23 °C for further 120 min. The reaction mixture was diluted with H_2O (10 mL) and the raw products were extracted using SPE. The solvent was evaporated under reduced pressure and the residue was purified *via* preparative HPLC (method A). Isolated **8** was transferred to its base-on form by treatment with 10% aq. NaOH, followed by washing with water. Crystallization from aqueous acetone furnished **8** (15.0 mg, 12 μmol , 59%) as a dark red crystalline solid. Co_α -phenylcobalamin was not isolated.

UV-vis (H_2O , $c = 6.4 \times 10^{-5}$ M): 267 (3.95), 283 (3.93), 342 (3.83), 374 (3.69), 475 (sh., 3.42), 520 (br., 3.58). UPLC: $t_{\text{ret}} = 2.52$ min (method 1). ESI-MS ($\text{H}_2\text{O}/\text{MeCN}$): $m/z = 703.96$ (100, $[\text{M} + 2\text{H}]^{2+}$), 1406.63 (7, $[\text{M} + \text{H}]^+$, $m/z_{\text{calc}}: 1406.61$ for $\text{C}_{68}\text{H}_{94}\text{CoN}_{13}\text{O}_{14}\text{P}^+$). $^1\text{H-NMR}$ (D_2O , $c = 3.2 \times 10^{-5}$ M): 7.22 (s, HC2N), 7.16 (s, HC7N), 6.79 (t, $J = 6.7$, HC4L), 6.74 (t, $J = 7.3$, HC3L , HC5L), 6.59 (s, HC4N), 6.23 (d, $J = 3.0$, HC1R), 5.96 (s, HC10), 5.83 (d, $J = 7.5$, HC2L , HC6L), 4.69–4.64 (m, HC3R), 4.30 (d, $J = 7.5$, HC16), 4.24–4.21 (m, HC3 , HC2R), 4.11–4.09 (m, HC4R), 3.92 (app. d, $J = 11.3$, H_a of $\text{H}_2\text{C5R}$), 3.73 (dd, $J = 12.8$, 3.8, H_b of $\text{H}_2\text{C5R}$), 3.52 (app. d, $J = 14.3$, H_a of $\text{H}_2\text{C175}$), 3.41–3.32 (m, 3 corrin-CH), 2.96 (dd, $J = 14.7$, 8.7 Hz, H_b of $\text{H}_2\text{C175}$), 2.73–2.56 (m, corrin-CH, 2 corrin-CH₂) superimposed by 2.73 (s, $\text{H}_3\text{C51}$) and 2.63 (s, $\text{H}_3\text{C151}$), 2.49–2.40 (m, 2 corrin-CH₂), 2.28 (s, $\text{H}_3\text{C10N}$), 2.22 (s, $\text{H}_3\text{C11N}$), 2.15–2.03 (m, 2 corrin-CH₂), 1.96–1.93 (m, corrin-CH₂), 1.89–1.63 (m, 4 corrin-CH₂) superimposed by 1.85 (s, $\text{H}_3\text{C7A}$), 1.40 (s, $\text{H}_3\text{C12A}$), 1.24 (s, $\text{H}_3\text{C2A}$), 1.21–1.09 (m, H_b of $\text{H}_2\text{C82}$) superimposed by 1.19 (d, $J = 6.8$, $\text{H}_3\text{C177}$) and 1.12 (s, $\text{H}_3\text{C17B}$), 0.97 (d, $J = 9.8$, H_b of $\text{H}_2\text{C81}$), 0.90 (s, $\text{H}_3\text{C12B}$), 0.47 (s, $\text{H}_3\text{C1A}$). Assignments were made in comparison with data from lit.¹³

Author contributions

F. Z. and C. B. designed the experiments and wrote the manuscript. C. B. and P. D. M. performed synthesis and characterization. C. B. executed the biological studies.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

A generous gift of vitamin B_{12} from DSM Nutritional Products AG (Basel/Switzerland) is acknowledged. This work was, in part, financially supported by the UZH 'Forschungskredit' (grant-no. FK-17-088 to C. B. and FK-20-096 to P. D. M.).

References

- 1 F. Zelder, M. Sonnay and L. Prieto, *ChemBioChem*, 2015, **16**, 1264–1278.
- 2 J. C. Somogyi and K. Trautner, in *Vitamine*, ed. R. Ammon, W. Dirscherl and G. Thieme, Stuttgart, 1974, 3, 10–138.
- 3 I. M. Kompis, K. Islam and R. L. Then, *Chem. Rev.*, 2005, **105**, 593–620.
- 4 G. Domagk, *Angew. Chem.*, 1935, **48**, 657–667.
- 5 C. Heidelberger, N. K. Chaudhuri, P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky, R. J. Schnitzer, E. Pleven and J. Scheiner, *Nature*, 1957, **179**, 663–666.
- 6 W. D. Zhou, E. W. Scocchera, D. L. Wright and A. C. Anderson, *MedChemComm*, 2013, **4**, 908–915.
- 7 F. Zelder and R. Alberto, in *The Porphyrin Handbook*, ed. K. M. Kadish, K. M. Smith and R. Guillard, Elsevier Science, San Diego, 2012, vol. 25, 83–130.
- 8 F. Zelder, K. Zhou and M. Sonnay, *Dalton Trans.*, 2013, **42**, 854–862.
- 9 S. P. Stabler, E. P. Brass, P. D. Marcell and R. H. Allen, *J. Clin. Invest.*, 1991, **87**, 1422–1430.
- 10 E. Mutti, M. Ruetz, H. Birn, B. Krautler and E. Nexo, *PLoS One*, 2013, **8**, 1–9, DOI: [10.1371/journal.pone.0075312](https://doi.org/10.1371/journal.pone.0075312).
- 11 R. Bonnett, J. R. Cannon, V. M. Clark, A. W. Johnson, L. F. J. Parker, E. L. Smith and A. Todd, *J. Chem. Soc.*, 1957, 1158–1168.
- 12 L. Prieto, J. Rossier, K. Derszniak, J. Dybas, R. M. Oetterli, E. Kottelat, S. Chlopicki, F. Zelder and F. Zobi, *Chem. Commun.*, 2017, **53**, 6840–6843.
- 13 C. Brenig, M. Ruetz, C. Kieninger, K. Wurst and B. Kräutler, *Chem.-Eur. J.*, 2017, **23**, 9726–9731.
- 14 F. Wagner, *Proc. R. Soc. A*, 1965, **288**, 344–347.
- 15 K. Zhou, R. Oetterli, H. Brandl, F. Lyatuu, W. Buckel and F. Zelder, *ChemBioChem*, 2012, **13**, 2052–2055.
- 16 R. M. Oetterli, L. Prieto, B. Spingler and F. Zelder, *Org. Lett.*, 2013, **15**, 4630–4633.
- 17 J. A. Valu, *Appl. Microbiol.*, 1965, **13**, 486–490.
- 18 L. Prieto, M. Neuburger, B. Spingler and F. Zelder, *Org. Lett.*, 2016, **18**, 5292–5295.
- 19 K. Zelenka, H. Brandl, B. Spingler and F. Zelder, *Dalton Trans.*, 2011, **40**, 9665–9667.
- 20 C. Brenig, L. Mosberger, K. Baumann, O. Blacque and F. Zelder, *Helv. Chim. Acta*, 2021, **104**, 1–9, DOI: [10.1002/hcl.202100067](https://doi.org/10.1002/hcl.202100067).
- 21 K. Kurumaya and M. Kajiwara, *Chem. Pharm. Bull.*, 1989, **37**, 9–12.
- 22 Z. Rzepka, M. Respondek, J. Rok, A. Beberok, K. O. Proinsias, D. Gryko and D. Wrzesniok, *Int. J. Mol. Sci.*, 2018, **19**, DOI: [10.3390/ijms19092845](https://doi.org/10.3390/ijms19092845).

